- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05268289
Estudio de eficacia y seguridad de LNP023 en participantes con nefritis lúpica activa clase III-IV, +/- V
Ensayo adaptativo, aleatorizado, doble ciego, de exploración de dosis, de grupos paralelos, controlado con placebo, multicéntrico de fase 2 para evaluar la eficacia, la seguridad y la tolerabilidad de LNP023 en combinación con el estándar de atención con y sin corticosteroides orales en pacientes con lupus activo Nefritis Clase III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Mainz, Alemania, 55131
- Novartis Investigative Site
-
-
Lower Saxony
-
Braunschweig, Lower Saxony, Alemania, 38126
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Alemania, 51109
- Novartis Investigative Site
-
-
-
-
-
Santa Fe, Argentina, S3000EPV
- Novartis Investigative Site
-
-
-
-
-
Salvador, Brasil, 40323-010
- Novartis Investigative Site
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 40150-150
- Novartis Investigative Site
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30150-221
- Novartis Investigative Site
-
Juiz de Fora, Minas Gerais, Brasil, 36010-570
- Novartis Investigative Site
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 05403-000
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 04038-002
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 01308-050
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombia, 230004
- Novartis Investigative Site
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Novartis Investigative Site
-
-
Cundinamarca
-
Bogota, Cundinamarca, Colombia, 111411
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombia, 680003
- Novartis Investigative Site
-
-
-
-
-
Barcelona, España, 08036
- Novartis Investigative Site
-
Ciudad Real, España, 13005
- Novartis Investigative Site
-
Madrid, España, 28034
- Novartis Investigative Site
-
Madrid, España, 28040
- Novartis Investigative Site
-
Seville, España, 41009
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Ronald Reagan UCLA Medical Center
-
San Bernardino, California, Estados Unidos, 92408
- Loma Linda University
-
Sylmar, California, Estados Unidos, 91342
- Olive View UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Denver
-
-
Florida
-
Hollywood, Florida, Estados Unidos, 33021
- Royal Research Corp
-
Orlando, Florida, Estados Unidos, 32806
- Nephrology Associates Of Central FL
-
Riverview, Florida, Estados Unidos, 33578
- Florida Kidney Physicians
-
-
Illinois
-
Hinsdale, Illinois, Estados Unidos, 60521
- Nep Assoc of Northern Illinois
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Wichita Community Clcl Onco Program
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Health System
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins Hospital
-
-
New York
-
East Setauket, New York, Estados Unidos, 11733
- Stony Brook Internists PC
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19140
- Temple University
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75204
- Dallas Nephrology Associates
-
Houston, Texas, Estados Unidos, 77054
- Prolato Clinical Research Center
-
-
-
-
-
Quezon, Filipinas, 1102
- Novartis Investigative Site
-
-
National Capital Region
-
Makati City, National Capital Region, Filipinas, 1218
- Novartis Investigative Site
-
-
-
-
-
Marseille, Francia, 13005
- Novartis Investigative Site
-
Nantes, Francia, 44093
- Novartis Investigative Site
-
-
-
-
Hong Kong
-
Hong Kong, Hong Kong, Hong Kong, 999077
- Novartis Investigative Site
-
-
-
-
-
Budapest, Hungría, 1083
- Novartis Investigative Site
-
Szeged, Hungría, 6725
- Novartis Investigative Site
-
-
Hajdu Bihar Megye
-
Debrecen, Hajdu Bihar Megye, Hungría, 4032
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kozhikode, Kerala, India, 673008
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, India, 110029
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, India, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, India, 226014
- Novartis Investigative Site
-
-
-
-
-
Selangor Darul Ehsan, Malasia, 68100
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malasia, 25100
- Novartis Investigative Site
-
-
Perak
-
Taiping, Perak, Malasia, 34000
- Novartis Investigative Site
-
-
-
-
-
Aguascalientes, México, 20230
- Novartis Investigative Site
-
Veracruz, México, 91900
- Novartis Investigative Site
-
-
Tamaulipas
-
Tampico, Tamaulipas, México, 89440
- Novartis Investigative Site
-
-
Yucatán
-
Mérida, Yucatán, México, 97070
- Novartis Investigative Site
-
-
-
-
-
Beijing, Porcelana, 100034
- Novartis Investigative Site
-
Shenzhen, Porcelana, 518036
- Novartis Investigative Site
-
-
Guangxi
-
Nanning, Guangxi, Porcelana, 530022
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Porcelana, 430022
- Novartis Investigative Site
-
-
Liaoning
-
Shenyang, Liaoning, Porcelana, 110004
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Porcelana, 750004
- Novartis Investigative Site
-
-
-
-
-
Carnaxide, Portugal, 2799-523
- Novartis Investigative Site
-
Coimbra, Portugal, 3004-561
- Novartis Investigative Site
-
Lisbon, Portugal, 1649-035
- Novartis Investigative Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Novartis Investigative Site
-
-
-
-
-
San Juan, Puerto Rico, 00927
- FDI Clinical Research
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Novartis Investigative Site
-
-
-
-
Singapore
-
Singapore, Singapore, Singapur, 308433
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul, Fatih, Turquía (Türkiye), 34093
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Turquía (Türkiye), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Turquía (Türkiye), 16059
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara, Yenimahalle, Turquía (Türkiye), 06500
- Novartis Investigative Site
-
-
Yenisehir
-
Mersin, Yenisehir, Turquía (Türkiye), 33110
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis.
Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS.
eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study.
First presentation or flare of lupus nephritis.
Exclusion Criteria:
Induction treatment with cyclophosphamide within 3 months of planned treatment for this study; treatment with calcineurin inhibitors within the previous 3 months prior to randomization.
Presence of rapidly progressive glomerulonephritis (RPGN) as defined by 50% decline in eGFR within 3 months prior to screening.
Renal biopsy presenting with interstitial fibrosis/tubular atrophy (IF/TA) or glomerulosclerosis of more than 50%, or which in the opinion of the investigator is such that it precludes likely response to immunosuppressive therapy.
Participants being treated with systemic corticosteroids (>5 mg/day prednisone or equivalent) for indications other than SLE or LN e.g. acute asthma, inflammatory bowel disease.
Participants being treated with systemic corticosteroids for SLE or LN will be excluded if they have taken more than an average of 15 mg/day prednisone (or equivalent) in the previous 4 weeks and more than an average of 30 mg/day in the previous 1 week Receipt of more than a total dose of 1000 mg equivalent i.v. pulse methylprednisolone (cumulative dose) within 2 weeks prior to enrollment (and at enrollment)
Other protocol-defined inclusion/exclusion criteria may apply
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Iptacopan + standard of care (part 1)
Iptacopan + standard of care |
Taken for 52 Weeks
Otros nombres:
|
|
Comparador de placebos: Placebo matching iptacopan + standard of care (part 1)
Placebo matching iptacopan standard of care |
Taken for 52 Weeks |
|
Comparador activo: Iptacopan + standard of care (part 2)
Iptacopan + standard of care |
Taken for 52 Weeks
Otros nombres:
|
|
Comparador activo: Iptacopan + placebo (part 2)
Iptacopan + placebo standard of care |
Taken for 52 Weeks
Otros nombres:
|
|
Comparador activo: Placebo matching iptacopan + standard of care (part 2)
Placebo matching iptacopan + standard of care |
Taken for 52 Weeks |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Part 1 and 2: Proportion of patients achieving Complete Renal Response (CRR) at week 24 in the absence of renal flares
Periodo de tiempo: Baseline and week 24
|
Part 1: To evaluate the proportion of patients achieving complete renal response with iptacopan treatment "A" plus standard of care, compared to treatment alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "B" plus standard of care, compared to treatment "D" alone Part 2: To evaluate the proportion of patients achieving complete renal response with Iptacopan treatment "C" plus standard of care, compared to treatment "D" alone Complete Renal Response is defined as meeting the following criteria: estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73 m2 or no less than 85% of baseline value, and 24h urine protein-to-creatinine ratio (UPCR) ≤ 0.5 g/g. |
Baseline and week 24
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Parts 1 and 2: Proportion of patients achieving CRR or PRR in the absence of renal flares
Periodo de tiempo: Baseline, week 24, week 52
|
Proportion of patients achieving complete renal response or partial renal response |
Baseline, week 24, week 52
|
|
Proportion of patients achieving ≥25% UPCR reduction in the absence of renal flares compared to baseline at week 24
Periodo de tiempo: Baseline, week 24 week 52
|
Frequency of renal flares between weeks 24 and 52 |
Baseline, week 24 week 52
|
|
Log-transformed ratio to baseline of 24h UPCR at week 24
Periodo de tiempo: Baseline week 24
|
Dose exposure response for reduction in proteinurea. (each 24h urine protein-to-creatinine ratio value will based on two 24 urine collections sampled within 10 days before the respective study visit) |
Baseline week 24
|
|
Change from baseline FACIT-Fatigue Score
Periodo de tiempo: Weeks 24 and 52
|
Measure fatigue in patients |
Weeks 24 and 52
|
|
Change from baseline in SLEDAI-2K score at weeks 24 and 52
Periodo de tiempo: Weeks 24 and 52
|
Measure disease activity in SLE |
Weeks 24 and 52
|
|
Change from baseline in BILAG-2004 score at weeks 24 and 52
Periodo de tiempo: Weeks 24 and 52
|
Measure disease activity |
Weeks 24 and 52
|
|
Time-to-Complete Renal Response (CRR) based on first morning void(FMV) urine samples
Periodo de tiempo: Week 24 and Week 52
|
Measurement of time to complete renal response based on urine samples |
Week 24 and Week 52
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Trastornos de la micción
- Manifestaciones Urológicas
- Glomerulonefritis
- Nefritis
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades de la piel y del tejido conectivo
- Signos y síntomas
- Lupus Eritematoso Sistémico
- Nefritis lúpica
- Proteinuria
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Calidad de la atención médica
- Indicadores de calidad, atención médica
- Estándar de cuidado
- iptacopan
Otros números de identificación del estudio
- CLNP023K12201
- 2021-002046-33 (Número EudraCT)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .